Difference between revisions of "Bivalirudin (Angiomax)"
m |
|||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Direct thrombin inhibitor, binds reversibly to free and clot-associated thrombin at its catalytic site and anion-binding exosite and inhibits its effects of catalyzing the formation of fibrin from fibrinogen, platelet aggregation, activation of protein C, and activation of coagulation factors V, VIII, and XIII.<ref name="insert">[http://www.angiomax.com/ | + | Class/mechanism: Direct thrombin inhibitor, binds reversibly to free and clot-associated thrombin at its catalytic site and anion-binding exosite and inhibits its effects of catalyzing the formation of fibrin from fibrinogen, platelet aggregation, activation of protein C, and activation of coagulation factors V, VIII, and XIII.<ref name="insert">[http://www.angiomax.com/downloads/ANG_USPI.pdf Bivalirudin (Angiomax) package insert]</ref><ref>[[Media:Bivalirudin.pdf | Bivalirudin (Angiomax) package insert (locally hosted backup)]]</ref><ref>[http://www.angiomax.com/ Angiomax manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 9: | Line 7: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *Brief patient counseling information can be found | + | *Brief patient counseling information can be found in the [http://www.angiomax.com/downloads/ANG_USPI.pdf Bivalirudin (Angiomax) package insert]<ref name="insert"></ref> |
*[http://www.uptodate.com/contents/bivalirudin-patient-drug-information Bivalirudin (Angiomax) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bivalirudin-patient-drug-information Bivalirudin (Angiomax) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/bivalirudin-patient-drug-information Bivalirudin (Angiomax) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bivalirudin-patient-drug-information Bivalirudin (Angiomax) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==Also known as== | ||
| + | Angiox | ||
==References== | ==References== | ||
Revision as of 23:46, 26 April 2017
General information
Class/mechanism: Direct thrombin inhibitor, binds reversibly to free and clot-associated thrombin at its catalytic site and anion-binding exosite and inhibits its effects of catalyzing the formation of fibrin from fibrinogen, platelet aggregation, activation of protein C, and activation of coagulation factors V, VIII, and XIII.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Brief patient counseling information can be found in the Bivalirudin (Angiomax) package insert[1]
- Bivalirudin (Angiomax) patient drug information (UpToDate)[4]
Also known as
Angiox